HK1257237A1 - 預防和治療脂肪肝的藥物及其用途 - Google Patents

預防和治療脂肪肝的藥物及其用途

Info

Publication number
HK1257237A1
HK1257237A1 HK18116273.4A HK18116273A HK1257237A1 HK 1257237 A1 HK1257237 A1 HK 1257237A1 HK 18116273 A HK18116273 A HK 18116273A HK 1257237 A1 HK1257237 A1 HK 1257237A1
Authority
HK
Hong Kong
Prior art keywords
medicine
preventing
fatty liver
treating fatty
treating
Prior art date
Application number
HK18116273.4A
Other languages
English (en)
Inventor
李季男
Original Assignee
深圳瑞健生命科學研究院有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 深圳瑞健生命科學研究院有限公司 filed Critical 深圳瑞健生命科學研究院有限公司
Publication of HK1257237A1 publication Critical patent/HK1257237A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK18116273.4A 2016-12-15 2018-12-19 預防和治療脂肪肝的藥物及其用途 HK1257237A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201611161347 2016-12-15
CN201611162237 2016-12-15

Publications (1)

Publication Number Publication Date
HK1257237A1 true HK1257237A1 (zh) 2019-10-18

Family

ID=62656680

Family Applications (7)

Application Number Title Priority Date Filing Date
HK18116273.4A HK1257237A1 (zh) 2016-12-15 2018-12-19 預防和治療脂肪肝的藥物及其用途
HK18116275.2A HK1257239A1 (zh) 2016-12-15 2018-12-19 預防和治療肥胖症的藥物及其用途
HK18116276.1A HK1257240A1 (zh) 2016-12-15 2018-12-19 預防和治療脂肪異常沉積導致的組織損傷的藥物及其用途
HK18116270.7A HK1257234A1 (zh) 2016-12-15 2018-12-19 治療冠狀動脈粥樣硬化及其併發症的藥物及其用途
HK18116272.5A HK1257236A1 (zh) 2016-12-15 2018-12-19 預防和治療高脂血症的藥物及其用途
HK18116269.0A HK1257233A1 (zh) 2016-12-15 2018-12-19 預防動脈粥樣硬化及其併發症的藥物及其用途
HK18116702.5A HK1257583A1 (zh) 2016-12-15 2018-12-28 預防和治療脂肪代謝紊亂及其相關病症的藥物及其用途

Family Applications After (6)

Application Number Title Priority Date Filing Date
HK18116275.2A HK1257239A1 (zh) 2016-12-15 2018-12-19 預防和治療肥胖症的藥物及其用途
HK18116276.1A HK1257240A1 (zh) 2016-12-15 2018-12-19 預防和治療脂肪異常沉積導致的組織損傷的藥物及其用途
HK18116270.7A HK1257234A1 (zh) 2016-12-15 2018-12-19 治療冠狀動脈粥樣硬化及其併發症的藥物及其用途
HK18116272.5A HK1257236A1 (zh) 2016-12-15 2018-12-19 預防和治療高脂血症的藥物及其用途
HK18116269.0A HK1257233A1 (zh) 2016-12-15 2018-12-19 預防動脈粥樣硬化及其併發症的藥物及其用途
HK18116702.5A HK1257583A1 (zh) 2016-12-15 2018-12-28 預防和治療脂肪代謝紊亂及其相關病症的藥物及其用途

Country Status (2)

Country Link
CN (8) CN108210914A (zh)
HK (7) HK1257237A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108671226A (zh) * 2018-08-08 2018-10-19 广州铭康生物工程有限公司 有效治疗中心静脉导管并发症的药物及其用途
CN110093412A (zh) * 2019-03-29 2019-08-06 南方医科大学南方医院 用于诊断动脉粥样硬化的分子标志物ugp2及应用
CN111100928A (zh) * 2020-01-09 2020-05-05 武汉科技大学 动脉粥样硬化生物标志物及动脉粥样硬化诊断试剂盒
US20230139956A1 (en) * 2020-02-26 2023-05-04 Talengen International Limited Method and drug for preventing and treating abnormal blood pressure condition
CN112305120B (zh) * 2020-10-30 2022-02-08 河北医科大学第二医院 代谢物在动脉粥样硬化性脑梗死中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1408431A (zh) * 2001-09-21 2003-04-09 北京华兴生生物技术有限公司 治疗与新生血管生成相关疾病的基因工程药物
JP2005525798A (ja) * 2002-02-06 2005-09-02 トロムスドルフ ゲーエムベーハー ウント コー．カーゲー アルツナイミッテル 微生物内での組み換えタンパク質の生産方法
AU2003301809A1 (en) * 2002-05-13 2004-06-07 Children's Hospital Los Angeles Treatment and prevention of abnormal scar formation in keloids and other cutaneous or internal wounds or lesions
CN100469370C (zh) * 2002-12-06 2009-03-18 法布罗根股份有限公司 一种稳定HIFα的制剂在制备调节脂肪代谢的药物中的应用
WO2004052856A1 (en) * 2002-12-10 2004-06-24 Wyeth Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
EP1666469A4 (en) * 2003-09-11 2008-12-03 Inst Med Molecular Design Inc INHIBITOR OF INHIBITOR-1 PLASMOGENIC ACTIVATOR
AU2005238464B2 (en) * 2004-04-22 2011-01-27 Grifols Therapeutics Inc. Recombinantly modified plasmin
WO2006095713A1 (ja) * 2005-03-08 2006-09-14 Institute Of Medicinal Molecular Design. Inc. プラスミノゲンアクチベータインヒビター－１阻害剤
JPWO2007111242A1 (ja) * 2006-03-24 2009-08-13 ロート製薬株式会社 メタボリック症候群改善剤
DK2056864T3 (en) * 2006-08-28 2014-03-10 Omnio Healer Ab CANDIDATES AGAINST INFECTION
AU2007309226B2 (en) * 2006-10-20 2012-09-20 Dow Global Technologies Llc Uses of water-soluble cellulose derivatives for preventing or treating metabolic syndrome
US20090239868A1 (en) * 2007-10-23 2009-09-24 Institute Of Medical Molecular Design, Inc. Inhibitor of pai-1 production
JP5470046B2 (ja) * 2007-10-23 2014-04-16 株式会社医薬分子設計研究所 Ｐａｉ−１産生抑制剤
CA2767612A1 (en) * 2009-07-10 2011-01-13 Thrombogenics Nv Variants of plasminogen and plasmin
CN107412724A (zh) * 2009-08-12 2017-12-01 康奈尔大学 预防或治疗代谢综合症的方法
EP2566890A4 (en) * 2010-05-03 2013-11-20 Abbvie Inc ANTI-PAI-1 ANTIBODIES AND METHOD FOR THEIR USE
ES2583082T3 (es) * 2011-01-05 2016-09-19 Thrombogenics N.V. Variantes de plasminógeno y plasmina
EP2680837A4 (en) * 2011-03-03 2015-06-03 Tersus Pharmaceuticals Llc COMPOSITIONS AND METHODS COMPRISING C16: 1N7-PALMITOLATE
CN102188699A (zh) * 2011-05-06 2011-09-21 南京农业大学 一种治疗动脉粥样硬化的药物组合物及其制备方法和应用
RU2604810C2 (ru) * 2011-08-12 2016-12-10 Тромбодженикс Н.В. Варианты плазминогена и плазмина
CN102532326B (zh) * 2011-11-18 2017-06-09 南京大学 一种肿瘤靶向的人纤溶酶原Kringle5变体及其应用
KR20160035077A (ko) * 2013-08-13 2016-03-30 사노피 플라스미노겐 활성인자 저해제-1(pai-1)에 대한 항체 및 그의 용도
WO2015026494A2 (en) * 2013-08-20 2015-02-26 Trustees Of Dartmouth College Methods for treating tissue fibrosis

Also Published As

Publication number Publication date
HK1257236A1 (zh) 2019-10-18
CN108210895A (zh) 2018-06-29
HK1257234A1 (zh) 2019-10-18
HK1257233A1 (zh) 2019-10-18
CN108210898A (zh) 2018-06-29
CN108210906A (zh) 2018-06-29
HK1257239A1 (zh) 2019-10-18
CN108210896A (zh) 2018-06-29
CN108210902A (zh) 2018-06-29
CN108210904A (zh) 2018-06-29
HK1257583A1 (zh) 2019-10-25
CN108210914A (zh) 2018-06-29
HK1257240A1 (zh) 2019-10-18
CN108210900A (zh) 2018-06-29

Similar Documents

Publication Publication Date Title
IL262416A (en) Materials and methods for the treatment of hemoglobin diseases
HK1252873A1 (zh) 用於癌症治療和預防的疫苗
SG10202101986UA (en) Tetracycline compounds and methods of treatment
SG11201706767RA (en) Materials and methods for treatment of hemoglobinopathies
HK1257237A1 (zh) 預防和治療脂肪肝的藥物及其用途
ZA201900960B (en) Methods and compositions for the treatment of cancer
HK1250950A1 (zh) 曲美他嗪在製備防治肝病的藥物中的用途
IL265955A (en) Therapeutic compounds and methods of use thereof
HK1259545A1 (zh) 用於治療癌症的bcl-2抑制劑和mek抑制劑組合產品
IL246779A0 (en) Methods for the treatment and prevention of kidney disorders and fatty liver disorders
IL254842B (en) Therapeutic preparations and methods for use in cancer treatment
GB2558021B (en) Composition for treatment and/or nutrition of poultry
IL266486A (en) Pharmaceutical preparations and methods for cancer treatment
HK1257587A1 (zh) 預防和治療肝纖維化的藥物及其用途
ZA201808232B (en) Compositions and methods for the treatment of cancer
ZA201900984B (en) Methods and compositions for the treatment of warts
HK1258056A1 (zh) 治療性化合物和其使用方法
GB201511799D0 (en) Composition and methods of treatment
GB201621737D0 (en) Compositions and methods of treatment
HK1249035A1 (zh) 降低成像後胰腺炎風險的組合物和方法
GB201605127D0 (en) Composition and methods of treatment
EP3225237A4 (en) Fatty acid amides for the prevention and/or treatment of steatohepatitis
GB201522936D0 (en) A combination of Chinese medicine treating fatty liver
GB201418640D0 (en) Agents and methods for treatment of cancer
AP2016009662A0 (en) Combination of taurine and racemethionine for treatment of liver diseases